Based on the high expression of uPAR on the surface of a variety of tumour cells, uPA/ATF/AE105/AE147/PAI-2/U11 modified nanoplatforms provide the possibility of reducing or overcoming the therapeutic limitations of conventional chemotherapy or PTT/PDT through targeted delivery to tumour cells without obvious toxicity to healthy tissue. This evidence concerns the gene SERPINB2 and neoplasm.